Transcriptomic Profiling Identifies Hub Transcription Factors Associated with the Protective Effects of Licochalcone A Against HFD-Induced MASLD

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) lacks approved specific pharmacological treatments and exhibits complex pathogenesis. Licochalcone A (LA), a flavonoid extracted from Glycyrrhiza glabra, possesses anti-inflammatory and lipid-modulating activities, yet its protective effects and transcriptional regulatory mechanisms against MASLD remain poorly defined.

Methods